What is Scitara?
Scitara operates as a global provider of lab-specific iPaaS solutions, fundamentally transforming how research and development, bioprocessing, and quality control labs manage their digital infrastructure. At the core of its offering is the DLX platform, a cloud-native architecture designed to automate data workflows, connect disparate lab instruments, and ensure rigorous data integrity. By addressing the critical need for interoperability in process-based industries, Scitara enables organizations to accelerate scientific discovery while maintaining compliance with stringent regulatory standards. The company's market position is defined by its ability to bridge the gap between legacy instrumentation and modern digital workflows, effectively serving as the connective tissue for the next generation of automated laboratories.
How much funding has Scitara raised?
Scitara has raised a total of $25M across 3 funding rounds:
Series A
$5M
Series B
$15M
Debt
$5M
Series A (2021): $5M with participation from Northpond Ventures LLC and Flybridge Capital Partners
Series B (2022): $15M led by Northpond Ventures and Flybridge Capital Partners
Debt (2026): $5M, investors not publicly disclosed
Key Investors in Scitara
Flybridge Capital Partners
Flybridge is an early-stage venture capital fund with over 20 years of investing experience and more than $1B under management, based in New York and Boston. The firm focuses on providing support to ambitious founders creating innovative companies centered around Artificial Intelligence.
Northpond Ventures
Northpond Ventures is a prominent investment firm specializing in science, technology, and healthcare, often backing companies that drive innovation in life sciences and digital health.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Scitara?
With this major enterprise-level funding, Scitara is well-positioned to scale its operations and deepen its footprint within the global bioprocessing and R&D sectors. The strategic allocation of this capital will likely focus on expanding the capabilities of the DLX platform, enhancing its automation features, and strengthening its expert support services. As the industry shifts toward fully digitized, AI-driven laboratory environments, Scitara's focus on data movement and integration will be critical in maintaining its competitive advantage. Future growth trajectories suggest a continued emphasis on enterprise-grade scalability, allowing the firm to support larger, more complex global deployments while maintaining the high standards of data reliability that have become synonymous with its brand.
See full Scitara company page
